Table 1.

Summary of the study visits

	Screening visit	Randomisation visit	First telephone interview	First follow-up visit	Second telephone interview	Second follow-up visit	Third follow-up visit	Third telephone interview
Gestation	11–13 weeks	11–14 weeks	16 weeks	19–24 weeks	28 weeks	32–34 weeks	36 weeks	30 days after the last dose of IMP
Patient information and characteristics	√
Informed consent	√	√
Measurement of weight and height	√			√		√	√
Measurement of MAP	√			√		√	√
Fetal ultrasound scan	√			√		√	√
Measurement of uterine artery PI	√			√		√	√
Measurement of PAPP-A and PlGF	√			√		√
Check concomitant medications		√	√	√	√	√	√
IMP dispensing		√		√
Ensure compliance			√	√	√	√	√
Check side effects/adverse events and review of diary card			√	√	√	√	√	√
Discontinue IMP							√

IMP, investigational medicinal product; MAP, mean arterial pressure; PlGF, placental growth factor; PAPP-A, pregnancy-associated plasma protein-A; PI, pulsatility index.